SPRO — Spero Therapeutics Share News
0.000.00%
Last trade - 00:00- $64.64m
- $13.87m
- $66.80m
U.S. STOCKS ON THE MOVE-Abercrombie & Fitch, Boston Scientific, DoorDash
Spero soars as UTI drug trial with partner GSK stops after early success
GSK, Spero to stop urinary tract infection drug trial due to early success (updated)
GSK, Spero to stop urinary tract infection drug trial due to early success
Spero Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Spero Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer
Spero Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Spero Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Spero Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Spero Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Spero Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Spero Therapeutics Q3 EPS USD -0.32
Spero Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Spero Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Spero Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Spero Therapeutics Q2 EPS USD -0.33
Spero Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Spero Therapeutics Inc reports results for the quarter ended in March - Earnings Summary